Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin

Nucleic Acids Research

Volumn 32, Issue 18, 2004, Pages 5546-5552

  Kasparkova, Jana ^b   Fojta, Miroslav ^b   Farrell, Nicholas ^a   Brabec, Viktor ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BBR 3464; CISPLATIN; DNA; OLIGODEOXYRIBONUCLEOTIDE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CULTURE MEDIUM; DNA MODIFICATION; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE TARGETING; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CISPLATIN; CONSENSUS SEQUENCE; DNA ADDUCTS; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; RESPONSE ELEMENTS; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9144264245     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkh896     Document Type: Article

References (41)

1. Farrell,N., Qu,Y., Bierbach,U., Valsecchi,M. and Menta,E. (1999) Structure-activity relationship within di- and trinuclear platinum phase I clinical agents. In Lippert,B. (ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. VHCA, WILEY-VCH, Zurich, Weinheim, pp. 479-496.
2. Farrell,N. (2000) Polynuclear charged platinum compounds as a new class of anticancer agents: Toward a new paradigm. In Kelland,L.R. and Farrell,N.P. (eds), Platinum-based Drugs in Cancer Therapy. Humana Press Inc, Totowa, NJ, pp. 321-338.
3. Farrell,N. (2004) Polynuclear platinum drugs. In Sigel,A. and Sigel,H. (eds), Metal Ions in Biological Systems. Marcel Dekker, Inc., New York, Basel, Hong Kong, Vol. 41, pp. 251-296.
4. Brabec,V., Kasparkova,J., Vrana,O., Novakova,O., Cox,J.W., Qu,Y. and Farrell,N. (1999) DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent. Biochemistry, 38, 6781-6790.
5. Zehnulova,J., Kasparkova,J., Farrell,N. and Brabec,V. (2001) Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J. Biol. Chem., 276, 22191-22199.
6. Kasparkova,J., Zehnulova,J., Farrell,N. and Brabec,V. (2002) DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem., 277, 48076-48086.
7. 4+ (BBR3464). Inorg. Chem. 41, 1101-1109.
8. McGregor,T.D., Bousfield,W., Qu,Y. and Farrell,N. (2002) Circular dichroism study of the irreversibility of conformational changes induced by polyamine-linked dinuclear platinum compounds. J. Inorg. Biochem., 91, 212-219.
9. Qu,Y., Scarsdale,N.J., Tran,M.C. and Farrell,N.P. (2003) Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites. J. Biol. Inorg. Chem., 8, 19-28.
10. Pratesi,P., Righetti,S.C., Supino,R., Pollizi,D., Manzotti,C., Giuliania,F.C., Pezzoni,G., Tognella,S., Sinelli,S., Perego,P. et al. (1999) High antitumor activity of a novel multinuclear platinum complex against cisplatin-resistant p53 mutant human tumors. Brit. J. Cancer, 80, 1912-1919.
11. O'Connor,P.M., Jackman,J., Bae,I., Myers,T.G., Fan,S., Mutoh,M., Scudiero,D.A., Monks,A., Sausville,E.A., Weinstein,J.N., Friend,S. et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57, 4285-4300.
12. Jordan,P. and Carmo-Fonseca,M. (2000) Molecular mechanisms involved in cisplatin eytotoxicity. Cell. Mol. Life Sci., 57, 1229-1235.
13. Riva,C.M. (2000) Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism. Anticancer Res., 20, 4463-4471.
14. Calvert,A.H., Thomas,H., Colombo,N., Gore,M., Earl,H., Sena,L., Camboni,G., Liati,P. and Sessa,C. (2001) Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer. Eur. J. Cancer, 37 (Suppl. 6), S260.
15. Orlandi,L., Colella,G., Bearzatto,A., Abolafio,G., Manzotti,C., Daidone,M.G. and Zaffaroni,N. (2001) Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. Eur. J. Cancer, 37, 649-659.
16. El-Deiry,W.S., Kern,S.E., Pietenpol,J.A., Kinzler,K.W. and Vogelstein,B. (1992) Definition of a consensus binding site for p53. Nature Genet., 1, 45-49.
17. Ahn,J. and Prives,C. (2001) The C-terminus of P53: the more you learn the less you know. Nature Struct. Biol., 8, 730-732.
18. Johnson,N.P., Butour,J.-L., Villani,G., Wimmer,F.L., Defais,M., Pierson,V. and Brabec,V. (1989) Metal antitumor compounds: The mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 10, 1-24.
19. May,P. and May,E. (1999) Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene, 18, 7621-7636.
20. Tokino,T., Thiagalingam,S., Eldeiry,W.S., Waldman,T., Kinzler,K.W. and Vogelstein,B. (1994) p53 tagged sites from human genomic DNA. Hum. Mol. Genet., 3, 1537-1542.
21. Nagaich,A.K., Zhurkin,V.B., Durell,S.R., Jernigan,R.L., Appella,E. and Harrington,R.E. (1999) p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. Proc. Natl Acad. Sci. USA, 96, 1875-1880.
22. Lebrun,A., Lavery,R. and Weinstein,H. (2001) Modeling multi-component protein-DNA complexes: the role of bending and dimerization in the complex of p53 dimers with DNA. Protein Eng., 14, 233-243.
23. Kasparkova,J., Pospisilova,S. and Brabec,V. (2001) Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. J. Biol. Chem., 276, 16064-16069.
24. Kartalou,M. and Essigmann,J.M. (2001) Recognition of cisplatin adducts by cellular proteins. Mutat. Res., 478, 1-21.
25. Brabec,V. (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. In Moldave,K. (ed.), Prog. Nucleic Acid Res. Mol. Biol. Academic Press Inc, San Diego, CA, Vol. 71, pp. 1-68.
26. Fojta,M., Pivonkova,H., Brazdova,M., Kovarova,L., Palecek,E., Pospisiluva,S., Vojtesek,B., Kasparkova,J. and Brabec,V. (2003) Recognition of DNA modified by antitumor cisplatin by 'latent' and 'active' protein p53. Biochem. Pharmacol., 65, 1305-1316.
27. Kasparkova,J., Farrell,N. and Brabee,V. (2000) Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J. Biol. Chem., 275, 15789-15798.
28. Hupp,T.R. and Lane,D.P. (1995) Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem., 270, 18165-18174.
29. Kim,S.D., Vrana,O., Kleinwächter,V., Niki,K. and Brabec,V. (1990) Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA. Anal. Lett., 23, 1505-1518.
30. Vojtesek,B., Bartek,J., Midgley,C.A. and Lane,D.P. (1992) An immunochemical analysis of the human nuclear phosphoprotein p53 - New monoclonal-antibodies and epitope mapping using recombinant p53. J. Immunol. Meth., 151, 237-244.
31. Mazur,S.J., Sakaguchi,K., Appella,E., Wang,X.W., Harris,C.C. and Bohr,V.A. (1999) Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. J. Mol. Biol., 292, 241-249.
32. Brazdova,M., Palecek,J., Cherny,D.I., Billuva,S., Fojta,M., Pecinka,P., Vojtesek,B., Juvin,T.M. and Palecek,E. (2002) Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Res., 30, 4966-4974.
33. Jamieson,E.R. and Lippard,S.J. (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 99, 2467-2498.
34. Gelasco,A. and Lippard,S.J. (1998) NMR solution structure of a DNA dudecamer duplex containing a cis-diammineplatinum(II) adduct d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry, 37, 9230-9239.
35. Takahara,P.M., Frederick,C.A. and Lippard,S.J. (1996) Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J. Am. Chem. Soc., 118, 12309-12321.
36. Brabec,V., Sip,M. and Leng,M. (1993) DNA conformational distortion produced by site-specific interstrand cross-link of trans diamminedichloroplatinum(II). Biochemistry, 32, 11676-11681.
37. Keck,M.V. and Lippard,S.J. (1992) Unwinding of supercoiled DNA by platinum ethidium and related complexes. J. Am. Chem. Soc., 114, 3386-3390.
38. Berners-Price,S.J., Davies,M.S., Cox,J.W., Thomas,D.S. and Farrell,N. (2003) Competitive reactions of interstrand and iotrastrand DNA-Pt adducts: A dinuclear-platinum complex preferentially forms a 1,4-interstrand cross-link rather than a 1,2 intrastrand cross-link on binding to a GG 14mer duplex. Chem. Eur. J., 9, 713-725.
39. Hegmans,A., Berners-Price,S.J., Davies,M.S., Thomas,D., Humphreys,A. and Farrell,N. (2004) Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove pre-association affects kinetics and mechanism of cross-link formation as well as adduct structure. J. Am. Chem. Soc., 126, 2166-2180.
40. Cho,Y., Gorina,S., Jeffrey,P.D. and Pavletich,N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346-355.
41. Nagaich,A.K., Zhurkin,V.B., Sakamoto,H., Gorin,A.A., Clore,G.M., Gronenborn,A.M., Appella,E. and Harrington,R.E. (1997) Architectural accommodation in the complex of four p53 DNA binding domain peptides with the p21/waf1/cip1 DNA response element. J. Biol. Chem. 272, 14830-14841.